Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan E Cohen

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Nature Biotechnology|January 22, 2021
Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of originRonen Sadeh, Israa Sharkia, Gavriel Fialkoff, et al.
Nature Biotechnology|March 2, 2021
Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of originRonen Sadeh, Israa Sharkia, Gavriel Fialkoff, et al.
Nature Biotechnology|January 12, 2021
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of originRonen Sadeh, Israa Sharkia, Gavriel Fialkoff, et al.
JCI Insight|January 25, 2022
Liquid biopsy reveals collateral tissue damage in cancerAsael Lubotzky, Hai Zemmour, Daniel Neiman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Cancer Discovery|May 1, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose EscalationRona Yaeger, Meredith A McKean, Rizwan Haq, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Nature Biotechnology|January 22, 2021
Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of originRonen Sadeh, Israa Sharkia, Gavriel Fialkoff, et al.
Nature Biotechnology|March 2, 2021
Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of originRonen Sadeh, Israa Sharkia, Gavriel Fialkoff, et al.
Nature Biotechnology|January 12, 2021
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of originRonen Sadeh, Israa Sharkia, Gavriel Fialkoff, et al.
JCI Insight|January 25, 2022
Liquid biopsy reveals collateral tissue damage in cancerAsael Lubotzky, Hai Zemmour, Daniel Neiman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Cancer Discovery|May 1, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose EscalationRona Yaeger, Meredith A McKean, Rizwan Haq, et al.
Pageof 5